{
  "abstract": "We present the case of radiation recall dermatitis (RRD) induced by ibrutinib therapy in a patient with a history of breast cancer and non-Hodgkin lymphoma. There is currently only one other reported case of Bruton’s tyrosine kinase (BTK) inhibitor therapy-induced RRD in a patient with breast cancer and chronic lymphocytic leukaemia. This case highlights a potentially under-recognised risk of RRD associated with BTK inhibitors, emphasising the need for further research to clarify its pathophysiology and incidence in this treatment context. A deeper understanding of the dermatological side effects of BTK inhibitors can help providers better anticipate, recognise and manage patient symptoms.",
  "authors": [
    {
      "affiliations": [
        "Department of Breast Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA"
      ],
      "name": "Mariana Restrepo"
    },
    {
      "affiliations": [
        "Dubin Breast Center of the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"
      ],
      "name": "Christina Weltz"
    },
    {
      "affiliations": [
        "Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"
      ],
      "name": "Sheryl Green"
    },
    {
      "affiliations": [
        "Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"
      ],
      "name": "Angela Lamb"
    },
    {
      "affiliations": [
        "Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA"
      ],
      "name": "Julie Fasano"
    }
  ],
  "title": "Radiation recall dermatitis following ibrutinib therapy in a patient with breast cancer and non-Hodgkin lymphoma",
  "uid": "c58d530f-d2f7-5bf3-a665-c18051f6f396"
}